Angiosarcoma gets orphan drug as Propranolol by EC

Release Date: 10-Feb-2017

European Commission has granted Orphan Drug Designation to Propranolol for the treatment of Angiosarcoma, a lethal form of soft tissue sarcoma. Propranolol has been commonly used in the treatment of high blood pressure.


The EMA’s designation of orphan status is granted to encourage new developments and therapies for rare diseases and disorders. Orphan status can be granted to those diseases that are rare. These incentives include protocol assistance, i.e. scientific advice specific for designated orphan medicines, and 10 years of market exclusivity once the medicine is on the market.


For Orphan Drug Clinical Insight Reports Contact:

Need custom market research solution? We can help you with that too.